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Abstract
The presence of autoantibodies in cancer has become relevant in recent years. We demonstrated that autoantibodies
purified from the sera of breast cancer patients activate muscarinic acetylcholine receptors in tumor cells. Immunoglobulin
G (IgG) from breast cancer patients in T1N0Mx stage (tumor size#2 cm, without lymph node metastasis) mimics the action
of the muscarinic agonist carbachol stimulating MCF-7 cell proliferation, migration and invasion. Angiogenesis is a central
step in tumor progression because it promotes tumor invasion and metastatic spread. Vascular endothelial growth factor-A
(VEGF-A) is the main angiogenic mediator, and its levels have been correlated with poor prognosis in cancer. The aim of the
present work was to investigate the effect of T1N0Mx-IgG on the expression of VEGF-A, and the in vivo neovascular
response triggered by MCF-7 cells, via muscarinic receptor activation. We demonstrated that T1N0Mx-IgG (1028 M) and
carbachol (1029 M) increased the constitutive expression of VEGF-A in tumor cells, effect that was reverted by the
muscarinic antagonist atropine. We also observed that T1N0Mx-IgG and carbachol enhanced the neovascular response
produced by MCF-7 cells in the skin of NUDE mice. The action of IgG or carbachol was reduced in the presence of atropine.
In conclusion, T1N0Mx-IgG and carbachol may promote VEGF-A production and neovascularization induced by breast
tumor cells via muscarinic receptors activation. These effects may be accelerating breast tumor progression.
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Introduction
The presence of autoantibodies (autoAbs) against tumor
associated antigens in the sera of cancer patients has been
previously reported [1]. Moreover, several studies reviewed by
Ferna´ndez Madrid et al. [1] indicate that a plethora of autoAbs
with different specificities has been found in breast cancer patients.
These spontaneous responses are frequently detected in 5 to 30%
of patients for one autoantigen. Chapman et al. [2] reported data
from breast carcinoma patients that confirmed that autoAbs to
tumor associated antigens can be measured up to four years before
mammography imaged the tumor. Their results also strengthen
previous ones, since they reported that the incidence of autoAbs,
to at least one of six tumor associated antigens (p53, c-myc, HER2,
NYESO-1, BRCA2, and MUC1) analyzed as a group rises to 64%
in the sera of breast carcinoma patients. These striking data imply
that the human immune system detects the tumor antigens as
‘‘nonself’’ and makes a humoral immune response very early in the
disease process. Even though the presence of autoAbs has been
extensively analyzed by sensible methods, the function of these
autoAbs during tumor progression has not been fully understood
yet. Emerging evidence indicates that most of the antigens
identified in human tumors are self-proteins without mutations
but inappropriately expressed or over-expressed [1].
Muscarinic acetylcholine receptors (mAChR) expression is up-
regulated in different types of tumors such as colon, lung, ovarian
and prostate tumors [3]. These receptors are part of the G-protein-
coupled receptors family, there are five different subtypes of them
(M1–M5), and they bind acetylcholine (ACh) [4]. Previous work in
our laboratory demonstrates that mAChR are over-expressed in
tissue from human breast cancer tumors in comparison to breast
normal tissue [5]. Moreover, IgG from patients with breast cancer
in early stages can promote tumor proliferation due to the
activation of mAChR [6]. Hence, autoAbs against mAChR could
be playing an important role in tumor growth.
One of the most important steps in tumor progression is
angiogenesis, the process that leads to tumor neovascularization by
new blood vessel formation to promote tumor growth and
metastatic spread [7]. The development of new capillaries is
regulated by a complex mechanism with the participation of pro-
angiogenic factors. Among them is the vascular endothelial growth
factor-A (VEGF-A), which stimulates endothelial cells survival,
proliferation and migration allowing the invasion of the surround-
ing tissue, and the formation of blood vessels. These functions are
triggered by the interaction of VEGF-A with its tyrosine kinase
receptors, which in turn transmits signals to various downstream
proteins [8]. Taking into account that previous studies indicate
that autoAbs against mAChR could have a role in tumor
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development, and the relevance of angiogenesis in tumor growth,
then we wanted to know if autoAbs against mAChR in breast
cancer patients could influence tumor angiogenic response. In
consequence, we investigated the role of autoAbs present in the
immunoglobulin G (IgG) fraction of breast cancer patients in stage
I on VEGF-A levels produced by MCF-7 cells and on tumor
neovascular response induced in an in vivo model, focusing on the
participation of mAChR. We demonstrated that IgG purified from
the sera of breast cancer patients in stage I increased the
constitutive expression of VEGF-A in tumor cells, effect that was
reverted by the muscarinic antagonist atropine. We also observed
that IgG enhanced the neovascular response produced by MCF-7
cells in the skin of NUDE mice. Both effects were similar to those
produced by the cholinergic agonist carbachol.
Materials and Methods
Selection of Patients
Cancer patients with breast adenocarcinoma in stage I were
selected in the Mastology Department of the Angel H. Roffo
Oncology Institute, University of Buenos Aires, and were classified
according to TNM criteria as T1N0Mx (tumor size#2 cm,
without axillary node metastasis). Subjects free of illness (normal)
or with breast benign fibroadenoma (BFA) were used as controls.
All of them were free of treatment, and blood samples (10–20 ml/
donor) were obtained at routine procedures before surgery.
Written informed consent was approved by the Ethics in Research
Committee from the A.H. Roffo Oncology Institute and was
obtained from each patient. This study was also approved by the
Figure 1. Effect of carbachol on VEGF-A expression in MCF-7 cells.Western blot assays were performed in A) supernatants (Sn) and B) lysates
(Lys) from MCF-7 and MCF-10A cells. Optical density (O.D.) of the bands was calculated by densitometric analysis, and values were relativized to the
expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). N. D. not detectable. One representative experiment of three is shown. Values
are mean 6 S.E.M. of three experiments. Molecular weights are indicated on the right. C) MCF-7 cells were treated for 1 h with 1029 M carbachol
(CARB) in the absence or presence of 1028 M atropine (AT), 4-diphenylacetoxi-N-methylpiperidine (4-DAMP), or tropicamide (TROP) and VEGF-A
expression was measured in Lys. Densitometric analysis of the bands is shown in lower panel. Values were relativized to the expression of VEGF-A in
MCF-7 cells without treatment, considered as 1, and is represented by a dotted line. Molecular weights are indicated on the right. Values are
mean6S.E.M of three experiments. *p,0.1; **p,0.01 vs. CARB.
doi:10.1371/journal.pone.0057572.g001
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Ethics Committee from the Centro de Estudios Farmacolo´gicos y
Bota´nicos (CEFYBO)-CONICET.
IgG Purification
After centrifugation of blood samples, sera were separated and
heat-inactivated at 56uC for 30 min. IgG purification was
performed by affinity chromatography in protein G-agarose
(Invitrogen Inc., Carlsbad, CA, USA). Samples (pH 6.0–7.5) were
loaded onto the column after equilibrating it with 10 volumes of
binding buffer: 0.01 sodium phosphate pH 7.0; 0.15 M NaCl at
high salt concentration. Elution was performed with 0.1 M glycine
hydrochloride (pH 2.6) and adjusted immediately to pH 7.0.
Concentration of proteins in the collected fractions was obtained
by measuring the absorbance at 280 nm, and fractions that
Figure 2. Effect of T1N0Mx-IgG on VEGF-A expression in MCF-7 cells.Western blot assays were performed in cell lysates (Lys) obtained from
A) untreated MCF-7 cells or treated with IgG from breast cancer patients in stage I (T1N0Mx-IgG) (1028 M) during 1 h in the absence or B) presence of
1028 M atropine (AT) 4-diphenylacetoxi-N-methylpiperidine (4-DAMP), or tropicamide (TROP). Densitometric analysis of the bands is shown. Values
were relativized to the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and to the expression of VEGF-A in MCF-7 cells without
treatment considered as 1, and is represented by a dotted line. Molecular weights are indicated on the right. Values are mean6S.E.M. of three
experiments. *p,0.01; **p,0.001 vs.T1N0Mx-IgG.
doi:10.1371/journal.pone.0057572.g002
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corresponded to the peak of maximal absorbance were stored at
220uC.
Cell Culture and Animals
The human breast adenocarcinoma cell line MCF-7 was
obtained from the American Type Culture Collection (ATCC;
Manassas, VI, USA), and cultured in Dulbecco’s modified Eagle’s
medium and F12 medium (DMEM:F12; 1:1; Invitrogen Inc.,
Carlsbad, CA, USA) with 2 mM L-glutamine, 80 mg/mL
gentamycin, supplemented with 10% heat inactivated fetal bovine
serum (FBS) (PAA laboratories GmbH, Haidmannweg, Austria) at
37uC in a humidified 5% CO2 air. MCF-10A cells were also
purchased by ATCC and constitute a non tumorigenic cell line
derived from human mammary tissue. Cells were grown on tissue
culture plastic dishes, in DMEM:F12 medium supplemented with
10% FBS, hydrocortisone (0.5 mg/ml), insulin (10 mg/ml), and
epidermal growth factor (20 ng/ml). The tumor cell line, LMM3,
was previously obtained from the murine syngeneic mammary
adenocarcinoma MM3 [9]. Cell cultures were maintained as
monolayers at 37uC and 5% CO2 in DMEM medium supple-
mented with 5% FBS. All cell lines were detached using the
following buffer: 0.25% trypsin and 0.02% EDTA in Ca2+ and
Mg2+-free phosphate buffer saline (PBS) of confluent monolayers.
The medium was replaced three times a week. Cell viability was
assayed by Trypan blue exclusion test, and the absence of
mycoplasma was confirmed by Hoechst staining [10].
Female NUDE mice or BALB/c mice, three months old, were
purchased from the colony of the animal facility of the National
Commission of Atomic Energy (CNEA, Buenos Aires, Argentina)
that were kept under specific pathogen-free conditions following
the protocol designed by the National Institute of Health (USA) in
the Guidelines for the care and handling of laboratory animals
(1986) and protocols were approved by the Internal Committee for
the Care and Use of Laboratory Animals (CICUAL) from the
School of Medicine, University of Buenos Aires.
Western Blot Assays
MCF-7, MCF-10A or LMM3 cells (26106/well) were seeded in
6-well plates with 1 ml of DMEM:F-12 medium (Invitrogen Inc.,
Carlsbad, CA, USA) plus 10% FBS. Then, cells were treated with
carbachol (1029 M), or 1028 M: T1N0Mx-, normal- or BFA-IgGs
during 1 h in the absence or presence of 1028 M muscarinic
antagonists: atropine, 4-diphenylacetoxi-N-methylpiperidine (4-
DAMP), or tropicamide that were added 30 min previous to
carbachol. After treatment, medium was replaced by fresh
medium plus 10% FBS. Supernatants from MCF-7, MCF-10A
or LMM3 cell cultures were collected after 24 h and stored at
280uC. Cells were washed twice with PBS and lysed in 1 ml of
modified RIPA buffer: 50 mM Tris–HCl pH 7.4, 50 mM NaCl,
5 mM NaF, 5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 5 mM
PMSF, 1% Triton X-100, 10 mg/ml trypsin inhibitor, 10 mg/ml
aprotinin, and 10 mg/ml leupeptin. After 1 h in ice bath, lysates
were centrifuged at 8,0006g for 20 min at 4uC. Resulting
supernatants were stored at 280uC, and protein concentration
was determined by the method of Bradford [11].
Cell lysates or supernatants (80 mg protein/lane) were subjected
to 12% sodium dodecyl sulfate-polyacrylamide minigels electro-
phoresis (SDS-PAGE). Then, proteins were transferred to
nitrocellulose membranes (Bio Rad) and were blocked in 20 mM
Tris-HCl buffer, 500 mM NaCl, and 0.05% Tween 20 (TBS-T)
with 5% skimmed milk for 1 h at 20uC to 25uC. The nitrocellulose
strips were subsequently incubated overnight with a specific rabbit
anti-VEGF-A antibody diluted 1:100 (Santa Cruz Biotechnology,
Inc. Santa Cruz, CA, USA) in TBS-T. After several rinses with
TBS-T, strips were incubated with the second antibody: goat anti-
rabbit IgG conjugated with horseradish peroxidase (HRP) diluted
1:20,000 (Sigma Chemical Co. St. Louis, MO, USA) in TBS-T
Figure 3. Effect of BFA-IgG and normal IgG on VEGF-A expression in MCF-7 cells. Tumor cells were treated with 1028 M benign
fibroadenoma (BFA) or normal-IgG during 1 h and Western blot assays were performed in MCF-7 cell A) supernatants (Sn) and B) lysates (Lys).
Densitometric analysis of the bands is shown. Values were relativized to the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and
to VEGF-A in MCF-7 cells without treatment considered as 1, and is represented by a dotted line. Molecular weights are indicated on the right. Values
are mean6S.E.M. of three experiments.
doi:10.1371/journal.pone.0057572.g003
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with 3% skimmed milk at 37uC during 1 h. Bands were detected
by enhanced chemiluminescence (ECL) [12]. Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) was used as loading control.
Quantification of the bands was performed by densitometric
analysis using Image J program (NIH) and was expressed in optical
density (O.D.) units relative to GAPDH.
Tumor Induced Angiogenesis
Tumor induced angiogenesis was quantified with an in vivo
bioassay previously described [13]. Briefly, tumor cell suspensions
were prepared by detaching and washing MCF-7, MCF-10A or
LMM3 cells twice with culture medium. Cell concentration was
adjusted to 26106 cells/ml in: DMEM:F-12 medium for MCF-7
and MCF-10A cells, or in DMEM medium for LMM3 cells.
Female NUDE mice were inoculated intradermically (i.d.) in both
flanks with 0.1 ml of MCF-7 or MCF-10A cell suspension. BALB/
c mice were also inoculated i.d. in both flanks with 0.1 ml of
LMM3 cell suspension. Before inoculation MCF-7 and LMM3
cells were treated during 1 h with 1028 M T1N0Mx-IgG or
1029 M carbachol in the absence or presence of 1028 M
muscarinic antagonists: atropine, 4-DAMP or tropicamide, added
30 min previous to IgG or carbachol. Normal-IgG or BFA-IgG
were used as control. Cells were washed before inoculation. After 5
days, the animals were sacrificed and skin removed by dissection of
adjacent tissues. The vascular response was observed in the inner
surface of the skin with a dissecting microscope (Konus USA
Corporation, Miami, FL) at a 6.46magnification, and the sites of
inoculation were photographed with an incorporated digital
camera (Canon Power Shot A75, Canon USA., Inc. Lake Success,
NY). Photographs were projected onto a reticular screen to count
the number of vessels per mm2 of skin. Angiogenesis was
quantified as vessel density (d), determined by the formula: S
number of vessels in each square/total number of squares. Since
MCF-7 tumor cells growth is estrogen dependent, animals were
treated with b-estradiol injected subcutaneously (0.1 mg/mice
Figure 4. Effect of T1N0Mx-IgG on VEGF-A expression in murine tumor cells. A) LMM3 and NMuMG cell lysates (Lys). Optical density (O.D.)
of the bands was calculated by densitometric analysis, and values were relativized to the expression of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). N. D. not detectable. One representative experiment of three is shown. Values are mean6S.E.M. Molecular weights are indicated on the
right. LMM3 cells were treated with B) T1N0Mx-IgG or C) carbachol (CARB) in the absence or presence of 1028 M atropine (AT). Densitometric analysis
of the bands is shown in the right pannel. Values were relativized to the expression of VEGF-A in LMM3 cells without treatment considered as 1, and is
represented by a dotted line. Values are mean6S.E.M. of three experiments. *p,0.01 vs. T1N0Mx-IgG or CARB. Molecular weights are indicated on the
right.
doi:10.1371/journal.pone.0057572.g004
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dissolved in 0.1 ml ethanol: water) five days before the adminis-
tration of tumor cells [14].
Drugs
All drugs were purchased from Sigma Chemical Co (St. Louis,
MI, USA) unless otherwise stated. Solutions were prepared fresh
daily.
Statistics
Results are given as means6S.E.M. of at least three indepen-
dent experiments. The statistical significance of differences
between means were analyzed by the analysis of variance using
GraphPad Prism 5; p,0.05 was considered to be statistically
significant. The analysis was complemented by using the Tukey
Figure 5. Effect of T1N0Mx-IgG or carbachol on MCF-7 cells-induced angiogenesis. MCF-7 cells were adjusted to 26106 cells/ml and
treated during 1 h with A) T1N0Mx-IgG (1028 M) or B) carbachol (CARB) (1029 M) in the absence or presence of 1028 M atropine (AT), 4-
diphenylacetoxi-N-methylpiperidine (4-DAMP), or tropicamide (TROP). Cell suspensions (0.1 ml) were inoculated (i.d.) in both flanks of NUDE mice.
Values are means6S.E. of three experiments performed in triplicate. Basal: animals without treatment. p,0.001 vs.T1N0Mx-IgG or CARB. Photographs
of the angiogenic sites from each experimental group stated in A) and B) are shown in upper panels. Magnification 6.46.
doi:10.1371/journal.pone.0057572.g005
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test to compare among mean values. Differences between means
were considered significant if p,0.05.
Results
Effect of Breast Cancer Patients’ IgG or Carbachol on
VEGF-A Expression in Tumor Cells. mAChR Participation
Since tumor cells usually express VEGF-A, we tested the
presence of this factor in MCF-7 cell supernatants and lysates. We
observed that tumor cells liberate VEGF-A into the cell culture
supernatant (Fig. 1A) and that VEGF-A is present in cell lysates
(Fig. 1B). We could not detect VEGF-A expression in normal
MCF-10A cells either in culture supernatants or in cell lysates
(Fig. 1A and B). Since we had previously demonstrated that MCF-
7 cells express functional mAChR subtypes 3 and 4, we tested the
action of carbachol on VEGF-A production by tumor cells. We
observed that 1029 M carbachol, significantly increased VEGF-A
production by 133630% in MCF-7 cells in comparison to control
(cells without treatment, considered as 100%) (Fig. 1C). In
addition, we observed that the action of carbachol was significantly
reduced by: the non selective muscarinic antagonist atropine
(42612%), by the M3 receptor antagonist 4-DAMP (5363%) or
by tropicamide (3768%) an M4 selective antagonist, confirming
the participation of these receptors in carbachol-induced VEGF-A
production by tumor cells.
Then we investigated the action of T1N0Mx-IgG obtained from
five different breast cancer patients in stage I, on VEGF-A
expression in MCF-7 cells. The addition of breast cancer patients’
IgG increased VEGF-A liberation by tumor cells into the culture
supernatants by 6467% in comparison to control (MCF-7 cells
without treatment) (Fig. 2A). We also demonstrated that
T1N0Mx-IgG increased by 151630% VEGF-A expression in
tumor cell lysates in comparison to control (Fig. 2B). To analyze
which subtype of mAChR was involved in the action of T1N0Mx-
IgG we tested its action in the presence of muscarinic antagonists
and we observed that atropine and 4-DAMP reduced IgG action
by 4166% and 50612% respectively and in a more potent
manner than tropicamide (34610%) (Fig. 2C, lower panel). We
also tested the action of normal-IgG or BFA-IgG (1028 M) (n = 3),
and we did not observe any effect on VEGF-A expression either in
the supernatants or in the lysates obtained from tumor cells in
comparison to control (MCF-7 cells without treatment, considered
as 1) (Fig. 3A and B).
In addition, we analyzed the ability of T1N0Mx-IgG to cross
react with mAChR present in LMM3 murine mammary tumor
cells, and to modulate VEGF-A expression. As it is shown in
Fig. 4A, LMM3 cells express this factor while normal murine
mammary cells NMuMG, do not. The addition of 1028 M
T1N0Mx-IgG potently up-regulated VEGF-A expression more
than 4 folds in cell lysates. This effect was significantly reduced by
atropine, revealing mAChR participation in this effect (Fig. 4B). As
a positive control, we evaluated the action of 1029 M carbachol on
murine tumor cells and it increased 1.5 fold VEGF-A protein
expression in LMM3 cell lysates (Fig. 4C).
Figure 6. Effect of T1N0Mx-IgG or carbachol on LMM3 cells-induced angiogenesis. Cells were adjusted to 26106 cells/ml and treated
during 1 h with T1N0Mx-IgG (1028 M) or carbachol (CARB) (1029 M) in the absence or presence of 1028 M atropine (AT). Cell suspensions (0.1 ml)
were inoculated (i.d.) in both flanks of BALB/c mice. Values are means6S.E. of three experiments performed in triplicate. Basal: animals without
treatment. Photographs of the angiogenic sites from each experimental group are shown in upper panels. Magnification 6.46.
doi:10.1371/journal.pone.0057572.g006
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Effect of IgG from Breast Cancer Patients and Carbachol
on Tumor-induced Angiogenesis. mAChR Participation
To complete these previous sets of experiments, we analyzed the
effect of T1N0Mx-IgG on the neovascular response induced by
MCF-7 cells in NUDE mice. We observed that human tumor cells
induced a potent angiogenic response (d= 1.8760.3) that was
significantly different from basal (untreated skin d= 1.1260.2)
(Fig. 5A). T1N0Mx-IgG, obtained from five different patients
increase tumor neovascularization (d= 3.1860.45) and we proved
that this effect was due to mAChR participation since the
preincubation of MCF-7 cells with atropine significantly reduced
this action (d= 2.2160.3 vs. MCF-7 cells without treatment;
p,0.1) (Fig. 5A). Photographs of the angiogenic site for each
experimental group are shown (Fig. 5A upper panels). The
addition of 1028 M normal-IgG or BFA-IgG did not modify the
angiogenic response induced by MCF-7 cells (normal-IgG
d= 1.8260.19, BFA-IgG d= 1.6760.21, p.0.05 vs MCF-7 cells
without treatment, n = 3). We confirmed that carbachol (1029 M)
activates mAChR expressed in tumor cells and increased the
neovascular response induced by them (59618%). The preincu-
bation of tumor cells with atropine reduced angiogenesis to basal
values (Fig. 5B). MCF-10A cells were unable to modify vessel
density in NUDE mice skin (d= 1.4660.39, p.0.05 in comparison
to control, untreated cells). Photographs of the vascular pattern
exerted by cells treated with carbachol in the skin of NUDE mice
for each experimental group are also shown (Fig. 5B).
In addition, we confirmed that T1N0Mx-IgG from breast
cancer patients was also able to increased neovascular response
induced by LMM3 cells in BALB/c mice by activating mAChR
(Fig. 6). Both T1N0Mx-IgG (1028 M) and carbachol (1029 M)
stimulated by 2562% and 3363% LMM3-induced vessels density
in murine skin, respectively (Fig. 6 lower panel). The preincuba-
tion of cells with atropine significantly reduced IgG and carbachol
action on LMM3- induced angiogenesis (p,0.001 vs. T1N0Mx-
IgG or carbachol). Photographs of the vascular pattern in the skin
of BALB/c mice exerted by LMM3 cells treated with T1N0Mx-
IgG or carbachol, for each experimental group are also shown
(Fig. 6 upper panel).
Discussion
Angiogenesis, the process that leads to tumor vascularization by
new blood vessel formation, is essential for tumor growth and
metastasis. It is a multistep and highly regulated process in which
pro-angiogenic and anti-angiogenic factors are involved [7].
VEGF is the most extensively studied angiogenic factor. The
mammalian VEGF family consists of five glycoproteins referred to
as VEGF-A, VEGF-B, VEGF-C, VEGF-D (also known as FIGF)
and placental growth factor (PlGF) also known as PGF [15]. The
best characterized of the VEGF family members is VEGF-A
(commonly referred to as VEGF), is a homodimeric protein of
nearly 45 kDa. It is expressed as various isoforms owing to
alternative splicing that leads to mature 121, 165, 189 and 206
amino-acid proteins, which differ in their molecular weights as
well as in their biological functions. The 121 isoform can diffuse
and is found free in different tissues, while 165, 189 and 206 are
associated to heparin with different strength. VEGF165 is the
predominant isoform and is commonly overexpressed in a variety
of human solid tumors [16]. As we observed in MCF-7 cells,
soluble and membrane isoforms of this factor are both present in
tumor cells, since we detected specific immunostaning either in the
supernatants or in cell lysates. It is also important to note that
normal MCF-10A cells did not show immunolabelling for VEGF-
A, and could not stimulate angiogenic response in NUDE mice,
these observations could be related with their inability to generate
malignant tumors in vivo.
Previous results from our laboratory evidenced that three
distinct cell lines LM2, LM3 and LMM3 originated from different
spontaneous mammary adenocarcinomas arising in BALB/c mice,
liberate high amounts of VEGF-A to the culture supernatants, and
also expressed this factor in the cell membrane [12]. In addition,
we also characterized mAChR expression in these cell lines, and
we observed that all of them express the five subtypes of mAChR
but LMM3 cells express 50 fold more receptor binding sites, and
are more metastatic than LM3 or LM2 cells [17,18]. We also
reported that the normal murine mammary NMuMG cells lack of
mAChR expression, similarly to human MCF-10A cells, and here
we showed that they are not VEGF-A producers [18]. Similarly,
we reported that human MCF-7 tumor cells, express mAChR
(subtypes 3 and 4), meanwhile human mammary normal cells
MCF-10A do not [19].
There is an important parallel between cancer and the systemic
autoimmune diseases, both are characterized by a diverse
collection of autoAbs directed against different antigens [20].
Most of the antigens identified in human tumors are self-proteins
without mutations but inappropriately expressed or over-expressed
[20]. We had previously described the presence of autoAbs in the
sera of mice LM3 tumor bearers [21]. These autoAbs recognize
and activate mAChR over-express in tumor cells, and promote
tumor growth and angiogenesis, revealing that mAChR could be
acting as autoantigens [21]. Recently, we identified a similar
population of autoAbs in the IgG fraction purified from the sera of
breast cancer patients in stage I [6]. Up to now, these autoAbs that
interact with mAChR have been detected in all female patients
studied with breast cancer in T1N0Mx [6,22]. T1N0Mx-IgGs
promote MCF-7 cell proliferation in vitro mainly through the
activation of M3 receptor subtype that triggers phospholipase C/
nitric oxide synthase metabolic pathway [22]. In addition,
T1N0Mx-IgGs increased MCF-7 cell migration and invasion by
up-regulating metalloproteinase-9 (MMP-9) activity in tumor cell
supernatants [22]. The roles of MMPs in metastasis are multifold.
They allow tumor cells to invade, intravasate and extravasate.
They also allow tumor cell migration in the extracellular matrix of
distant site, as well as growth and angiogenesis of secondary
tumors [23]. Regarding angiogenesis, here we demonstrate that
the same autoAbs that increased MMP-9 activity in MCF-7 cell
supernatants can trigger VEGF-A expression and tumor-induced
angiogenesis. On line with these results, Hawinkels et al. [24]
reported that MMP-9 mRNA in gastric cancer tissues was up-
regulated and coincided with VEGF expression and microvascular
density. These findings support an emerging notion that MMP-9 is
a positive regulator of tumor angiogenesis. Moreover, the latter
authors showed that neutrophil-derived MMP-9 was able to
release the biologically active VEGF165 from the extracellular
matrix of colon cancer [24].
It is important to note that the stimulation of MCF-7 cells-
induced neovascular response triggered by T1N0Mx-IgG was not
totally reduced in the presence of atropine, indicating that these
autoAbs could be exerting pro-angiogenic actions independently
of mAChR activation, and thus deepening the effects that favor
tumor growth.
Our results demonstrate that T1N0Mx-IgG were also able to
up-regulate VEGF-A expression and angiogenesis induced by
LMM3 cells in a more potent manner than in MCF-7 cells via
muscarinic activation. This could be due the differences in the
subtypes and amounts of mAChR express in both types of tumor
cells as we reported previously: LMM3 cells express high amounts
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of the five subtypes of mAChR while MCF-7 cells only express M3
and M4 receptor subtypes [18,19].
In conclusion our results indicate that T1N0Mx-IgG from
breast cancer patients in stage I potentiate VEGF-A production
and neovascular response induced by MCF-7 tumor cells by
activating mAChR express in them. These autoAbs could be
considered as risk factors in breast cancer progression.
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